Advertisement

Nonalcoholic Fatty Liver Disease

Published:November 17, 2022DOI:https://doi.org/10.1016/j.ecl.2022.06.007

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Endocrinology and Metabolism Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cusi K.
        • Isaacs S.
        • Barb D.
        • et al.
        American association of clinical endocrinology (AACE) clinical practice guideline for the diagnosis and management of non-alcoholic fatty liver disease in primary care and endocrinology settings.
        Endocr Pract. 2022; 28: 528-562
        • Kanwal F.
        • Shubrock J.
        • Adams L.
        • et al.
        Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.
        Gastroenterology. 2021; 161: 1657-1669
        • Chalasani N.
        • Younossi Z.
        • Lavine J.
        • et al.
        The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases.
        Hepatology. 2018; 67: 328-357
        • Diehl A.
        • Day C.
        Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis.
        N Engl J Med. 2017; 377: 2063-2072
        • Younossi A.
        • Henry L.
        Fatty liver through the ages: nonalcoholic steatohepatitis.
        Endocr Pract. 2022; 28: 204-213
        • Ludwig J.
        • Viggiano T.
        • McGill D.
        • et al.
        Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.
        Mayo Clin Proc. 1980; 55: 434-438
        • Eslam M.
        • Sanyal A.
        • George J.
        • et al.
        MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver Disease.
        Gastroenterology. 2020; 158: 1999-2014.e1
        • Loomba R.
        • Friedman S.
        • Shulman G.
        • et al.
        Mechanisms and disease consequences of nonalcoholic fatty liver disease.
        Cell. 2021; 184: 2537-2564
        • Dulai P.
        • Singh S.
        • Patel J.
        • et al.
        Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.
        Hepatology. 2017; 65: 1557-1565
        • Simon T.
        • Roelstraete B.
        • Khalili H.
        • et al.
        Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
        Gut. 2021; 70: 1375-1382
        • Younossi Z.
        • Corey K.
        • Alkhouri N.
        • et al.
        Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.
        Aliment Pharmacol Ther. 2020; 52: 513-526
        • Harrison S.
        • Gawrieh S.
        • Roberts K.
        • et al.
        Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
        J Hepatol. 2021; 75: 284-291
        • Younossi Z.
        • Golabi P.
        • de Avila L.
        • et al.
        The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.
        J Hepatol. 2019; 71: 793-801
        • Bril F.
        • Cusi K.
        Management of Nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.
        Diabetes Care. 2017; 40: 419-430
        • Cusi K.
        A Diabetologist’s Perspective of Non-alcoholic Steatohepatitis (NASH): knowledge gaps and future directions.
        Liver Int. 2020; 40: 82-88
        • Lomonaco R.
        • Leiva E.
        • Bril F.
        • et al.
        Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening.
        Diabetes Care. 2021; 44: 399-406
        • Cusi K.
        Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes.
        Diabetes Care. 2020; 43: 275-279
        • Baratta F.
        • Pastori D.
        • Angelico F.
        • et al.
        Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study.
        Clin Gastroenterol Hepatol. 2020; 18: 2324-2331.e4
        • Khan R.
        • Bril F.
        • Cusi K.
        • et al.
        Modulation of insulin resistance in nonalcoholic fatty liver disease.
        Hepatology. 2019; 70: 711-724
        • Grundy S.
        • Cleeman J.
        • Daniels S.
        • et al.
        Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.
        Circulation. 2005; 112: 2735-2752
        • Hannah W.
        • Harrison S.
        Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease.
        Clin Liver Dis. 2016; 20: 339-350
        • Budd J.
        • Cusi K.
        Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease.
        Curr Diab Rep. 2020; 20: 59
        • Chavez C.
        • Cusi K.
        • Kadiyala S.
        The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD.
        J Clin Endocrinol Metab. 2022; 107: 29-38
        • Sanyal A.
        • Chalasani N.
        • Kowdley K.
        • et al.
        Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
        N Engl J Med. 2010; 362: 1675-1685
        • Kargiotis K.
        • Athyros V.
        • Giouleme O.
        • et al.
        Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
        World J Gastroenterol. 2015; 21: 7860-7868
        • Aminan A.
        • Al-Kurd A.
        • Wilson R.
        • et al.
        Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis.
        JAMA. 2021; 326: 2031-2042